# US 8,278,273 B2 · Methods of enhancing functioning of the large intestine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,273 B2
- Document ID: US8278273B2
- Status: Granted
- Kind: B2
- Application number: 13/102,533
- Filed: 2011-05-06
- Published: 2011-11-10
- Granted: 2012-10-02
- Earliest claimed: 1997-05-02
- Assignees: 1149336 Ontario Inc.
- Inventors: Daniel J. Drucker
- Web page: https://patentgrep.com/patent/US8278273B2

## CPC

- A61K 38/26: Glucagons
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/605: Glucagons
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.

## Claims

### Claim 1

A method for treating a subject to enhance functioning of the large intestine, wherein the subject has undergone partial or subtotal resection of the large intestine, the method comprising the step of delivering to the large intestine of the subject a glucagon-like peptide-2 (GLP-2) receptor agonist in an amount effective to enhance functioning of the large intestine.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the GLP-2 receptor agonist is GLP-2 or a peptidic analog thereof which retains the GLP-2 receptor agonist function.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the subject is a human.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the analog of GLP-2 is resistant to cleavage by DPP-IV.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the analog of GLP-2 is selected from the group consisting of [D-Ala2]rGLP-2, [Gly2]rGLP-2, [Val2]rGLP-2, and [Gly2]hGLP-2.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the analog of GLP-2 is [Gly2]hGLP-2.

### Claim 7

A method of treating a subject to proliferate the tissue of the large intestine, wherein the subject has undergone partial or subtotal resection of the large intestine, the method comprising the step of delivering to the large intestine of the subject a GLP-2 receptor agonist in an amount effective to proliferate the tissue of the large intestine.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the GLP-2 receptor agonist is GLP-2 or a peptidic analog thereof which retains the GLP-2 receptor agonist function.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the subject is a human.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the analog of GLP-2 has enhanced large intestine cell proliferating activity relative to native rat GLP-2.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the analog of GLP-2 is resistant to cleavage by DPP-IV.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the analog of GLP-2 is selected from the group consisting of [D-Ala2]rGLP-2, [Gly2]rGLP-2, [Val2]rGLP-2, and [Gly2]hGLP-2.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the analog of GLP-2 is [Gly2]hGLP-2.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the analog of GLP-2 is delivered to the large intestine by oral, subcutaneous, or rectal administration.
